Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 19, 2012
- Accepted August 13, 2012
- First Published December 12, 2012.
Article Versions
- Previous version (December 12, 2012 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- Mark D. Cossburn, MRCP,
- Katharine Harding, MRCP,
- Gillian Ingram, PhD,
- Tariq El-Shanawany, MD,
- Adrian Heaps, PhD,
- Trevor P. Pickersgill, MBBch,
- Stephen Jolles, MD and
- Neil P. Robertson, MD
- Mark D. Cossburn, MRCP,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katharine Harding, MRCP,
NONE
NONE
Travel grant from Biogen Idec to attend theAssociation of British Neurologists Annual Meeting inBrighton, UK, on the 28th and 29th May 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gillian Ingram, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tariq El-Shanawany, MD,
(1) Advisory board, Hayward Medical/Viriopharma(2) Advisory board, Meda/Epipen(3) MonoPepT1De-1b trial data safety monitoring board
NONE
Speaker honoraria from ALKTravel funding from ALK, CSL, BPL, Octapharma, Baxter and Grifols
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Adrian Heaps, PhD,
NONE
NONE
1) Commercial: Phadia UK/Thermo-Fisher): Travel fee and Speaker honoraria (March 2011).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) Phadia UK (Thermo-Fisher): reagent costs for an unrelated study (2010-2012).
NONE
NONE
1) Association of Clinical Biochemistry (ACB): Scholarship Award 2010 reagent costs for an unrelated study.2) Association of Clinical Biochemistry (ACB): Scholarship Award 2011 reagent costs for an unrelated study.3) National Institute for Social Care and Health Research (NISCHR) Clinical Research Assistantship 2012-2015 for unrelated studies.
NONE
NONE
NONE
NONE
NONE
NONE
- Trevor P. Pickersgill, MBBch,
Served on Advisory Boards for Biogen-Idec and Teva (2009)
NONE
Travel and registration fee sponsorship for ECTRIMS 2004-8 (Merck-Serono); AAN 2008/ECTRIMS 2009-10 (Biogen-Idec);ECTRIMS 2011 (Novartis)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
British Medical Association (Director) - received honoraria and travel expenses
NONE
NONE
Previous owner of stock in Genzyme Corp. 2009-11.
NONE
NONE
- Stephen Jolles, MD and
(1) CSL Behring(2)Baxter(3)Shire(4)Octapharma(5)Viropharma(6)Thermofisher(7)Biotest(8)BPL(9)Swedish Orphan Biovitrum(10)Meda
NONE
NONE
(1)Clinical and Experimental Immunology, Editorial Board, 4 years
(1)Use of IVIg in TB
NONE
NONE
(1) CSL Behring(2)Baxter(3)Shire(4)Octapharma(5)Viropharma(6)Thermofisher(7)Biotest(8)BPL(9)Swedish Orphan Biovitrum(10)Meda
NONE
NONE
NONE
(1)CSL Behring(2)Shire(3)Thermofisher(4)BPL(5)Association of Clinical Biochemists
(1)NISCHR - 3 year 1/10th salary
(1)Honorary Senior Lecturer, UHW(2)Training Program Director Immunology for Wales
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Neil P. Robertson, MD
NONE
NONE
NONE
Journal of Neurology, Journal club editor May 2012 to current
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University (M.D.C., K.H., G.I., N.P.R.), and The Clinical Neurosciences Directorate (T.P.P.) and Department of Immunology, Cardiff and Vale University Local Health Board (T.E.-S., A.H., S.J.), University Hospital of Wales, Cardiff, UK.
- Correspondence to Dr. Robertson: robertsonnp{at}cf.ac.uk
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.